These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 15042621)
1. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Gao S; Liu GZ; Wang Z Prostate; 2004 May; 59(2):214-25. PubMed ID: 15042621 [TBL] [Abstract][Full Text] [Related]
2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
4. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626 [TBL] [Abstract][Full Text] [Related]
5. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Hsieh TC; Wu JM Anticancer Res; 2000; 20(1A):225-8. PubMed ID: 10769659 [TBL] [Abstract][Full Text] [Related]
6. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Mitchell SH; Zhu W; Young CY Cancer Res; 1999 Dec; 59(23):5892-5. PubMed ID: 10606230 [TBL] [Abstract][Full Text] [Related]
7. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566 [TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705 [TBL] [Abstract][Full Text] [Related]
9. Using DNA microarray analyses to elucidate the effects of genistein in androgen-responsive prostate cancer cells: identification of novel targets. Takahashi Y; Lavigne JA; Hursting SD; Chandramouli GV; Perkins SN; Barrett JC; Wang TT Mol Carcinog; 2004 Oct; 41(2):108-119. PubMed ID: 15378649 [TBL] [Abstract][Full Text] [Related]
10. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616 [TBL] [Abstract][Full Text] [Related]
12. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Wang J; Eltoum IE; Lamartiniere CA Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738 [TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
14. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Kai L; Levenson AS Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Yuan H; Pan Y; Young CY Cancer Lett; 2004 Sep; 213(2):155-63. PubMed ID: 15327830 [TBL] [Abstract][Full Text] [Related]
16. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Paliouras M; Diamandis EP Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304 [TBL] [Abstract][Full Text] [Related]
17. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432 [TBL] [Abstract][Full Text] [Related]
18. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Mukherjee B; Mayer D Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894 [TBL] [Abstract][Full Text] [Related]
19. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells. Götz C; Bachmann C; Montenarh M Prostate; 2007 Feb; 67(2):125-34. PubMed ID: 17044081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]